15.44

8.48% -1.43

Pre-market: 15.58 0.14 +0.91%

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $15.44, with a volume of 2.73M. It is down -8.48% in the last 24 hours and down -29.24% over the past month. Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Previous Close:

$16.87

Open:

$16.6

24h Volume:

2.73M

Relative Volume:

3.13

Market Cap:

$993.64M

Revenue:

Net Income/Loss:

$-221.04M

P/E Ratio:

-4.1569

EPS:

-3.7143

Net Cash Flow:

$-178.65M

1W Performance:

-27.72%

1M Performance:

-29.24%

6M Performance:

+13.20%

1Y Performance:

+156.05%

1-Day Range:

$14.80

$16.88

1-Week Range:

$14.80

$21.88

52-Week Range:

$5.68

$23.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

109

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	15.44	993.64M	0	-221.04M	-178.65M	-3.7143
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Initiated	Citigroup	Buy
Feb-02-26	Initiated	Guggenheim	Buy
Aug-21-25	Resumed	H.C. Wainwright	Buy
Jun-11-25	Resumed	Stifel	Buy
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

07:05 AM

CGEM Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus

07:05 AM

Sep 24, 2026

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Investing News Network

Sep 24, 2026

Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances By Investing.com - Investing.com Canada

Sep 24, 2026

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - finance.yahoo.com

Sep 24, 2026

Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - finance.yahoo.com

Sep 24, 2026

Cullinan Therapeutics (CGEM) Sets Q4 2026 Clinical Updates Amid High Price-to-Sales Valuation - GuruFocus

Sep 24, 2026

Cullinan Therapeutics Highlights Fourth Quarter 2026 - GlobeNewswire

Sep 24, 2026

Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - finance.yahoo.com

Sep 24, 2026